Stem Cells News and Research

RSS

Stem cells have the remarkable potential to develop into many different cell types in the body during early life and growth. In addition, in many tissues they serve as a sort of internal repair system, dividing essentially without limit to replenish other cells as long as the person or animal is still alive. When a stem cell divides, each new cell has the potential either to remain a stem cell or become another type of cell with a more specialized function, such as a muscle cell, a red blood cell, or a brain cell.

Tel Aviv University researchers invent new tool to control risk of runaway stem cells

Stem cell research holds promise for improving the quality of human life ― especially embryonic stem cells, which can potentially develop into any tissue in the human body. However, basic scientific problems still remain unresolved -- but Tel Aviv University researchers are leading the way to inventive solutions.

9 Jun 2010

New technique to prevent tumours developing in connection with stem cell transplantations

Researchers at Lund University have come up with a new technique to prevent tumours developing in connection with stem cell transplantations. The results have been published today in the respected scientific journal PNAS.

8 Jun 2010

$UC-MSCT improves symptoms, biochemical values in patients with severe refractory SLE: Study$

UC-MSCT improves symptoms, biochemical values in patients with severe refractory SLE: Study

A new study shows that umbilical cord mesenchymal stem cell transplant may improve symptoms and biochemical values in patients with severe refractory systemic lupus erythematosus.

8 Jun 2010

USPTO grants ISCO patent to International Stem Cell's hpSC

International Stem Cell Corporation, www.intlstemcell.com, announced today that the United States Patent and Trademark Office has granted ISCO patent number 7,732,202, the first of several pending patents relating to its development of human parthenogenetic Stem Cells. Human parthenogenetic stem cells are a new type of pluripotent stem cell that allows immune matching to potentially solve critical immune rejection problems, and does not involve the ethical issues that surround the use of fertilized human embryos.

8 Jun 2010

Research project to transform primary care practices into patient-centered medical homes concludes

An unprecedented research project into how to transform primary care practices into patient-centered medical homes has concluded with the release of a new eight-paper supplement to the May/June issue of Annals of Family Medicine.

8 Jun 2010

New technology involving adipose stem cells may one day cure patients with severe wounds: Researchers

New technology developed by University of Virginia inventors involving adipose stem cells - adult stem cells found in fatty tissue - could one day be used to treat patients with severe wounds and other serious conditions.

8 Jun 2010

Scientists combine two agents to treat patients with multiple myeloma

Scientists from the Barbara Ann Karmanos Cancer Institute in Detroit presented data showing that by combining two treatment agents in the care of multiple myeloma patients, doctors can use higher dosages of chemotherapy before autologous stem cell transplant while alleviating painful and debilitating side effects like severe oral mucositis (mouth ulcers).

8 Jun 2010

$Hana Biosciences reports complete data from Marqibo Phase 2 RALLY trial for relapsed/refractory adult ALL$

Hana Biosciences reports complete data from Marqibo Phase 2 RALLY trial for relapsed/refractory adult ALL

Hana Biosciences Inc.,, today announced complete data from its pivotal, Phase 2 RALLY clinical trial for Marqibo® (vincristine sulfate liposome injection) for the treatment of relapsed/refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL). Results from the RALLY trial demonstrated compelling evidence of single-agent, anti-leukemic activity in an advanced, heavily pre-treated, adult ALL population.

8 Jun 2010

XCell-Center GmbH announces approval of clinical trial in patients with chronic spinal cord injury

XCell-Center GmbH, Europe's leading provider of adult autologous stem cell therapy, announced approval of the first placebo controlled double blind clinical trial in patients with chronic spinal cord injury.

7 Jun 2010

PTC receives $5.4M SDD Award to support development of drugs that target Bmi-1

PTC Therapeutics, Inc. today announced the receipt of a $5.4 million Seeding Drug Discovery Award from The Wellcome Trust to support the development of drugs that target Bmi-1, a protein that has been linked to drug resistant cancers.

7 Jun 2010

Cytheris completes €12 million Series D financing

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has completed a €12 million ($15 million) Series D financing.

7 Jun 2010

Millennium reports on data of VELCADE for multiple myeloma from 2010 ASCO oral presentations

Millennium: The Takeda Oncology Company today reported on data from oral presentations of VELCADE® (bortezomib) for Injection based therapy in multiple myeloma presented at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO). These data highlight VELCADE based therapy in both transplant and non-transplant eligible previously untreated multiple myeloma patients, as well as VELCADE used as induction and/or maintenance therapy.

7 Jun 2010

AMG 386 demonstrates antitumor activity in Phase 2 trial involving patients with recurrent ovarian cancer

Amgen today announced that AMG 386, combined with paclitaxel, demonstrated antitumor activity in a randomized Phase 2 trial involving 161 patients with recurrent ovarian cancer. The results are being presented for the first time in an oral presentation at the 2010 American Society of Clinical Oncology Annual Meeting.

7 Jun 2010

Onyx reports encouraging ORR from ongoing Carfilzomib Phase 2 study for multiple myeloma

Onyx Pharmaceuticals, Inc. today announced interim results from an ongoing Phase 2 study, known as the 004 study. Carfilzomib, a selective, next-generation proteasome inhibitor, demonstrated encouraging overall response rates (ORR), tolerability and durable disease control when administered as a single-agent in patients with relapsed and/or refractory multiple myeloma.

7 Jun 2010

Positive data on retreatment with brentuximab vedotin in Hodgkin lymphoma, ALCL presented at ASCO

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today reported data on Hodgkin lymphoma and systemic anaplastic large cell lymphoma (ALCL) patients retreated with single-agent brentuximab vedotin (SGN-35). Preliminary data demonstrate that objective responses were achieved in seven out of 11 retreatment experiences and that brentuximab vedotin was well-tolerated in the retreatment setting.

7 Jun 2010

Health overhaul supporters plan $25 million promotion campaign

The New York Times: "Close allies of the Obama administration, seeking to rally the public behind President Obama's landmark health care bill, are planning to spend $25 million over the next five years to promote the measure and beat back mischaracterizations of it that could harm Democratic candidates. Mr. Obama's former communications director, Anita Dunn, and longtime Democratic strategist Andrew Grossman, have teamed up to form two new tax-exempt groups.

7 Jun 2010

New book highlights specific aspects of salivary gland development

Salivary glands are of utmost importance for several physiological functions ranging from the protection of teeth and surrounding soft tissues to the lubrication of the oral cavity, which is crucial for speech and perception of food taste.

5 Jun 2010

John Theurer Cancer Center to showcase treatment advancements for cancer at ASCO 2010

The John Theurer Cancer Center at Hackensack University Medical Center announced today important research findings that will be presented at the American Society of Clinical Oncology annual meeting taking place June 4 - 8, 2010 in Chicago. Research highlights include a comparison of first-line treatments for an aggressive form of lymphoma, the efficacy and safety of a new genetically engineered cancer therapy, and the value of a commonly used tool for staging lymphoma.

5 Jun 2010

WRNp controls key step in pluripotent stem cell differentiation: Study

A gene shown to play a role in the aging process appears to play a role in the regulation of the differentiation of embryonic stem cells, according to researchers from the Center for Stem Cell Biology and Regenerative Medicine and the Department of Medicine at Thomas Jefferson University.

5 Jun 2010

Biomet Biologics initiates enrollment in MarrowStim P.A.D. Kit IDE trial for critical limb ischemia

Biomet, a global leader in the manufacture of orthopedic and biotechnology products, announced today that its subsidiary, Biomet Biologics, has enrolled the first subject into its multicenter, prospective, randomized, double-blind, placebo-controlled clinical trial for critical limb ischemia (CLI).

5 Jun 2010

Stem Cells News and Research

Further Reading

Tel Aviv University researchers invent new tool to control risk of runaway stem cells

New technique to prevent tumours developing in connection with stem cell transplantations

UC-MSCT improves symptoms, biochemical values in patients with severe refractory SLE: Study

USPTO grants ISCO patent to International Stem Cell's hpSC

Research project to transform primary care practices into patient-centered medical homes concludes

New technology involving adipose stem cells may one day cure patients with severe wounds: Researchers

Scientists combine two agents to treat patients with multiple myeloma

Hana Biosciences reports complete data from Marqibo Phase 2 RALLY trial for relapsed/refractory adult ALL

XCell-Center GmbH announces approval of clinical trial in patients with chronic spinal cord injury

PTC receives $5.4M SDD Award to support development of drugs that target Bmi-1

Cytheris completes €12 million Series D financing

Millennium reports on data of VELCADE for multiple myeloma from 2010 ASCO oral presentations

AMG 386 demonstrates antitumor activity in Phase 2 trial involving patients with recurrent ovarian cancer

Onyx reports encouraging ORR from ongoing Carfilzomib Phase 2 study for multiple myeloma

Positive data on retreatment with brentuximab vedotin in Hodgkin lymphoma, ALCL presented at ASCO

Health overhaul supporters plan $25 million promotion campaign

New book highlights specific aspects of salivary gland development

John Theurer Cancer Center to showcase treatment advancements for cancer at ASCO 2010

WRNp controls key step in pluripotent stem cell differentiation: Study

Biomet Biologics initiates enrollment in MarrowStim P.A.D. Kit IDE trial for critical limb ischemia

Event guide: Supply Chain & Logistics for Cell & Gene Therapy eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo